VEGFA and neoplasm: Preclinical data indicate that high doses of anti-VEGF agents lead to increased deposition of the extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumor immune cells, such as monocytic and granulocytic MDSCs [54–56].